# TGFBR1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The TGFBR1 gene encodes a transmembrane serine/threonine kinase receptor, the principal type I receptor for TGF-β superfamily cytokines, essential for transducing extracellular signals that regulate cell proliferation, differentiation, apoptosis, and extracellular matrix remodeling. - Germline mutations in TGFBR1 are causative for connective tissue disorders such as Loeys-Dietz syndrome (LDS1) and Multiple Self-Healing Squamous Epithelioma (MSSE), characterized by vascular abnormalities and skin tumors, respectively. - TGFBR1's canonical signaling pathway involves phosphorylation of SMAD2/3 by activated TGFBR1 (following TGFBR2-mediated GS domain phosphorylation), leading to nuclear translocation and transcriptional regulation, while non-canonical pathways activate MAPK, PI3K/AKT, and Rho GTPase signaling. - Pathogenic mutations, particularly missense variants in the kinase domain (e.g., p.M253I) and GS domain, disrupt receptor activation and signaling, leading to diverse clinical phenotypes with genotype-phenotype correlations observed in LDS. - Somatic alterations and specific polymorphisms (e.g., TGFBR1*6A) contribute to tumorigenesis in various cancers, and the receptor is a validated therapeutic target for small-molecule kinase inhibitors like galunisertib. - Extensive post-transcriptional regulation by numerous microRNAs (e.g., miR-140-5p, miR-98) targeting the long 3' UTR of TGFBR1 mRNA plays a critical role in modulating receptor expression and downstream signaling in both physiological and pathological contexts. --- ## Executive Summary & Key Metadata The **Transforming Growth Factor Beta Receptor 1 (TGFBR1)** gene encodes a serine/threonine kinase transmembrane receptor that serves as the principal type I receptor for the TGF-β superfamily of cytokines. This receptor is indispensable for transducing extracellular TGF-β signals into intracellular phosphorylation cascades that regulate cell proliferation, differentiation, apoptosis, extracellular matrix remodeling, and immune modulation. Germline mutations in TGFBR1 underlie a spectrum of connective tissue disorders, most notably Loeys-Dietz syndrome (LDS) and Multiple Self-Healing Squamous Epithelioma (MSSE), while somatic alterations contribute to tumorigenesis across multiple cancer types. The receptor has emerged as a high-value therapeutic target, with small-molecule kinase inhibitors such as galunisertib in clinical development. | Attribute | Detail | |---|---| | **HGNC Symbol** | TGFBR1 | | **UniProt Accession** | P36897 | | **Representative PDB ID** | 1B6C (kinase domain), 2PJY (extracellular domain) | | **Chromosomal Locus** | 9q22.33 | | **Primary Molecular Function** | Serine/threonine protein kinase; TGF-β type I receptor; signal transduction | | **Disease & Pathology Associations** | Loeys-Dietz syndrome type 1 (LDS1), Multiple Self-Healing Squamous Epithelioma (MSSE), thoracic aortic aneurysm and dissection (TAAD), various cancers, congenital heart defects | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The TGFBR1 gene is located on the **long arm of chromosome 9 at cytogenetic band 9q22.33** (GRCh38/hg38 coordinates: chr9:99,103,647-99,154,192). The gene spans approximately **50.5 kilobases** of genomic DNA and is oriented on the minus strand. The genomic architecture comprises **9 coding exons** and 8 intervening introns, with the coding sequence distributed across approximately 1.5 kilobases of mature mRNA [1][2]. The 5' untranslated region (UTR) contains a canonical TATA-less promoter with multiple GC-rich regions, consistent with a housekeeping-like expression pattern, though expression levels vary substantially across tissues. The promoter region harbors binding sites for transcription factors including **SP1, AP-1, and SMAD proteins**, enabling both basal and inducible expression [3]. The 3' UTR is exceptionally long (~2.5 kb) and contains multiple AU-rich elements and microRNA (miRNA) response elements, making TGFBR1 mRNA a target for extensive post-transcriptional regulation by miRNAs including miR-140-5p, miR-181a, miR-22, miR-98, miR-4458, miR-769-5p, and miR-766-3p [4][5][6][7][1][2][3][4]. ### 1.2 Alternative Splicing and Isoforms Alternative splicing of TGFBR1 generates multiple transcript variants. The canonical transcript (NM_004612.4) encodes the full-length 503-amino acid receptor protein. A well-characterized alternatively spliced isoform, **TGFBR1*6A**, results from the deletion of exon 1 (encoding the signal peptide and part of the extracellular domain) and produces a protein lacking 14 amino acids in the extracellular domain [5][6]. This variant exhibits reduced signaling capacity and has been associated with increased cancer susceptibility, particularly for breast, colorectal, and ovarian cancers [5][6]. Additional splice variants affecting exon 5 have been described. Differential splicing of exon 5 produces isoforms with distinct signaling properties, and pathogenic variants affecting this splicing event cause either LDS or MSSE depending on the specific splice outcome [7][1]. The exon 5 region encodes part of the juxtamembrane domain containing the GS domain (glycine-serine rich region), which is critical for receptor activation. ### 1.3 Regulatory Elements and Enhancers Chromatin immunoprecipitation studies have identified multiple enhancer elements within intronic regions of TGFBR1. A regulatory region in intron 4 contains binding sites for **CEBPB**, which directly upregulates TGFBR1 expression in endothelial cells and contributes to atherosclerosis pathogenesis [2]. The long non-coding RNA **ANRIL** upregulates TGFBR1 expression in pulmonary fibroblasts by sequestering let-7d-5p, thereby relieving miRNA-mediated repression of TGFBR1 mRNA [3]. Similarly, the lncRNA **Linc00511** promotes TGFBR1 expression in non-small-cell lung cancer by sponging miR-98-5p [4]. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The TGFBR1 protein (UniProt P36897) is a 503-amino acid single-pass transmembrane receptor with a molecular weight of approximately 56 kDa (unglycosylated). The protein is organized into distinct functional domains from the N-terminus to the C-terminus: | Domain | Residues | Function | |---|---|---| | Signal peptide | 1-33 | Directs membrane insertion | | Extracellular ligand-binding domain | 34-126 | Binds TGF-β ligands; contains 10 conserved cysteine residues forming 5 disulfide bonds | | Transmembrane domain | 127-147 | Hydrophobic α-helix spanning the plasma membrane | | Juxtamembrane/GS domain | 148-200 | Contains the GS box (residues 185-204) with the T204 activation site | | Serine/threonine kinase domain | 201-490 | Catalytic domain with ATP-binding pocket and substrate recognition sites | | C-terminal tail | 491-503 | Regulatory region | ### 2.2 Extracellular Domain The extracellular domain (ECD) adopts a three-finger toxin fold, a structural motif shared with members of the TGF-β receptor superfamily. The ECD contains a characteristic arrangement of disulfide bonds that stabilize the ligand-binding interface. Structural studies of the TGFBR1 ECD in complex with TGF-β1 and TGFBR2 have revealed that the type I receptor binds the TGF-β dimer at a stoichiometry of 1:1:2 (TGFBR1:TGFBR2:TGF-β), with the ECD making critical contacts with the "wrist" region of the TGF-β dimer [3]. ### 2.3 GS Domain and Activation Mechanism The GS domain (residues 185-204) is a defining feature of type I TGF-β receptors. This region contains the conserved sequence **SGSGSGLPLLVQRTIARTIV**, which includes the critical threonine residue **T204**. Phosphorylation of T204 by the constitutively active TGFBR2 kinase is the initiating event in TGFBR1 activation. The GS domain forms a rigid α-helix in the inactive state, and phosphorylation induces a conformational change that releases the kinase domain from autoinhibition [3]. ### 2.4 Kinase Domain The serine/threonine kinase domain (residues 201-490) adopts the canonical bilobed protein kinase fold. The N-terminal lobe (residues 201-300) contains the ATP-binding pocket with the conserved glycine-rich loop (GXGXXG motif) and the critical lysine residue **K232** that coordinates ATP binding. The C-terminal lobe (residues 301-490) contains the catalytic loop with the conserved **HRDLKSSN** motif and the activation segment. The kinase domain phosphorylates downstream SMAD proteins at the C-terminal SXS motif (SSXS) [3]. ### 2.5 Structural Basis of Pathogenic Mutations Pathogenic missense mutations in TGFBR1 cluster predominantly in the kinase domain. Mutations affecting residues involved in ATP binding (e.g., K232), catalytic activity (e.g., D351), or structural stability of the kinase domain (e.g., M253) disrupt receptor signaling [5][6][7]. The p.M253I mutation (c.759G>A) identified in LDS families resides in the N-terminal lobe of the kinase domain and likely disrupts hydrophobic packing interactions essential for kinase stability [6]. Mutations in the GS domain, such as those affecting T204, impair receptor activation by preventing phosphorylation-dependent conformational changes [1][2]. ### 2.6 Interactive 3D Visualization [Interactive 3D Protein Visualizer: Load TGFBR1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P36897) The interactive visualizer enables exploration of the TGFBR1 three-dimensional structure, including domain organization, key catalytic residues, and the spatial distribution of clinically relevant mutations. Users can toggle between the inactive and active conformations, highlight the ATP-binding pocket, and visualize the GS domain phosphorylation site. ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical TGF-β/SMAD Signaling Pathway TGFBR1 functions as the obligate signaling receptor for TGF-β ligands (TGF-β1, TGF-β2, TGF-β3). The signaling cascade is initiated when the TGF-β dimer binds to the constitutively active type II receptor (TGFBR2), which then recruits TGFBR1 into a heterotetrameric complex (2:2:2 stoichiometry). Within this complex, TGFBR2 phosphorylates TGFBR1 at the GS domain, specifically at T204 and adjacent serine residues. This phosphorylation event relieves the autoinhibitory interaction between the GS domain and the kinase domain, activating TGFBR1's catalytic activity [3]. Activated TGFBR1 then phosphorylates receptor-regulated SMADs (R-SMADs), specifically **SMAD2** and **SMAD3**, at the C-terminal SXS motif. Phosphorylated SMAD2/3 form heterotrimeric complexes with the common mediator **SMAD4** and translocate to the nucleus, where they regulate transcription of target genes in cooperation with various transcription factors [3]. ```mermaid sequenceDiagram participant TGFB as "TGF-β Ligand" participant R2 as "TGFBR2" participant R1 as "TGFBR1" participant SMAD as "SMAD2/3" participant SMAD4 as "SMAD4" participant NUC as "Nucleus" TGFB->>R2: Ligand binding R2->>R1: Recruitment & phosphorylation (T204) R1->>SMAD: Phosphorylation (SXS motif) SMAD->>SMAD4: Complex formation SMAD4->>NUC: Nuclear translocation NUC->>NUC: Transcriptional regulation ``` ### 3.2 Non-Canonical Signaling Pathways Beyond the canonical SMAD pathway, TGFBR1 activates multiple non-SMAD signaling cascades: **MAPK/ERK Pathway**: TGFBR1 can activate Ras, Raf, MEK, and ERK through phosphorylation of SHC and recruitment of GRB2-SOS complexes. This pathway is particularly important in epithelial-mesenchymal transition (EMT) and cell migration [2]. **PI3K/AKT Pathway**: TGFBR1 directly interacts with and phosphorylates the p85 regulatory subunit of PI3K, leading to AKT activation. This pathway promotes cell survival and proliferation and is frequently dysregulated in cancer [3]. **Rho-like GTPase Pathways**: TGFBR1 activates RhoA, Rac1, and Cdc42 through PAR6-mediated mechanisms, regulating cytoskeletal reorganization and cell motility. **TRAF6/p38/JNK Pathway**: TGFBR1 recruits TRAF6, which activates TAK1 and downstream p38 and JNK MAPKs, contributing to apoptosis and inflammatory responses. ### 3.3 Regulation and Feedback Mechanisms TGFBR1 signaling is tightly regulated at multiple levels: **Ligand sequestration**: Extracellular antagonists including latent TGF-β binding proteins (LTBPs), follistatin, and decorin sequester TGF-β ligands and prevent receptor activation. **Receptor endocytosis**: Upon ligand binding, the TGFBR1/TGFBR2 complex undergoes clathrin-mediated endocytosis, which is required for SMAD signaling. Alternatively, caveolin-mediated endocytosis targets the receptor complex for degradation [3]. **Inhibitory SMADs**: SMAD6 and SMAD7 function as negative regulators. SMAD7 recruits the E3 ubiquitin ligases SMURF1 and SMURF2 to the activated receptor complex, promoting receptor ubiquitination and proteasomal degradation. **Phosphatases**: Protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) dephosphorylate TGFBR1, attenuating signaling. **MicroRNA regulation**: Numerous miRNAs directly target the TGFBR1 3'UTR and downregulate receptor expression. These include miR-140-5p (renal fibrosis, Wilms tumor), miR-181a (adipocyte differentiation), miR-22 (myoblast proliferation), miR-98 (cardiac fibrosis), miR-4458 (hepatocellular carcinoma), miR-769-5p (lung cancer), miR-766-3p (fracture healing), and miR-337-3p (cervical cancer) [4][5][6][7][1][2][3][4][4]. ### 3.4 Protein-Protein Interaction Network TGFBR1 participates in an extensive protein-protein interaction network. Key interaction partners include: - **TGFBR2**: The type II receptor that phosphorylates and activates TGFBR1 - **SMAD2/3**: Direct substrates phosphorylated by TGFBR1 - **SMAD7**: Inhibitory SMAD that recruits SMURF ubiquitin ligases - **TRAF6**: E3 ubiquitin ligase mediating non-canonical signaling - **PAR6**: Scaffold protein linking TGFBR1 to RhoA degradation - **FKBP12**: Immunophilin that binds the GS domain and prevents basal activation - **STRAP**: WD40-repeat protein that stabilizes the receptor-SMAD7 complex - **ZNF507**: Transcription factor that activates TGFBR1 expression in prostate cancer [5] - **CEBPB**: Transcription factor directly upregulating TGFBR1 in endothelial cells [2] ### 3.5 Biological Functions TGFBR1-mediated signaling regulates diverse biological processes: **Embryonic Development**: TGFBR1 is essential for gastrulation, left-right asymmetry, and cardiovascular development. Knockout mice die at embryonic day 9.5 due to defective yolk sac hematopoiesis and vasculogenesis [3]. **Extracellular Matrix Homeostasis**: TGFBR1 signaling stimulates collagen and fibronectin synthesis while inhibiting matrix metalloproteinase expression, maintaining tissue integrity. Dysregulation contributes to fibrosis in multiple organs [2][3][5]. **Immune Regulation**: TGFBR1 signaling in T cells promotes regulatory T cell differentiation and suppresses effector T cell responses, maintaining peripheral immune tolerance [6]. **Cell Cycle Control**: TGFBR1 signaling induces cell cycle arrest through upregulation of p15INK4B, p21CIP1, and p27KIP1, and downregulation of c-Myc and cyclin-dependent kinases [3]. **Epithelial-Mesenchymal Transition**: TGFBR1 activation induces EMT, a process critical for embryonic morphogenesis and cancer metastasis [2]. ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Loeys-Dietz Syndrome Type 1 (LDS1) Loeys-Dietz syndrome is an autosomal dominant connective tissue disorder characterized by arterial tortuosity, hypertelorism, bifid uvula, and aggressive aortic aneurysms. TGFBR1 mutations account for approximately 20-25% of LDS cases [5][6][7][1][2][3][4][5][6][7]. **Mutation Spectrum**: Over 100 pathogenic TGFBR1 variants have been identified in LDS patients. These include missense, nonsense, frameshift, and splice-site mutations distributed throughout the gene, with a predominance in the kinase domain [5][1][4]. The p.M253I (c.759G>A) variant is a recurrent mutation associated with classic LDS1 [6]. Other recurrent mutations include p.R487P, p.T200I, and p.D400G [1]. **Genotype-Phenotype Correlations**: Mutations affecting the kinase domain generally produce more severe cardiovascular phenotypes with earlier onset of aortic dissection [5][4]. Loss-of-function mutations, including nonsense and frameshift variants, are associated with a spectrum of phenotypes ranging from classic LDS to milder nonsyndromic aortopathy [1][5][2]. A novel nonsense mutation (p.R487*) was identified in a fetus with untypical LDS1 presenting with short long bones [6]. **Clinical Features**: LDS1 patients exhibit craniofacial abnormalities (hypertelorism, cleft palate, bifid uvula), skeletal anomalies (pectus deformities, scoliosis, arachnodactyly), and vascular manifestations including aortic root aneurysms, arterial tortuosity, and dissection [5][7][4]. The vascular phenotype is particularly aggressive, with a high risk of dissection at young ages and at smaller aortic diameters compared to Marfan syndrome [1][3]. **Prenatal Presentation**: TGFBR1 variants can cause severe prenatal phenotypes. A novel likely pathogenic variant was associated with severe ventriculomegaly and macrocephaly in a fetus [3]. Another case presented prenatally with short long bones and untypical LDS1 features [6]. ### 4.2 Multiple Self-Healing Squamous Epithelioma (MSSE) MSSE, also known as Ferguson-Smith syndrome, is an autosomal dominant skin disorder characterized by the development of multiple keratoacanthoma-like skin tumors that undergo spontaneous regression [1][4][7][1][2][5][6]. **Mutation Spectrum**: MSSE is caused by a distinct spectrum of TGFBR1 mutations, predominantly affecting the extracellular domain and the GS domain [7][1][6]. These mutations impair receptor signaling through dominant-negative mechanisms. A specific mutation, c.664G>A (p.G222R), was identified in a patient with features of both MSSE and LDS [2]. **Mechanism**: MSSE-associated mutations in the extracellular domain disrupt ligand binding, while GS domain mutations impair receptor activation. The resulting haploinsufficiency or dominant-negative effects reduce TGF-β signaling in keratinocytes, promoting uncontrolled proliferation and tumor formation [7][1][6]. **Genotype-Phenotype Overlap**: A single TGFBR1 variant can produce both MSSE and LDS phenotypes in the same patient [1][4][2]. This phenotypic diversity is explained by differential effects on TGF-β signaling: mutations that severely impair signaling cause LDS, while those with milder effects predispose to MSSE [7][1]. ### 4.3 Thoracic Aortic Aneurysm and Dissection (TAAD) TGFBR1 mutations contribute to both syndromic and nonsyndromic forms of TAAD [1][3][7][7][1][1][2][3][4]. The p.M253I mutation was identified in a patient with abdominal aortic aneurysm complicated by type B thoracic aortic dissection [7]. Nonsyndromic TAAD caused by TGFBR1 mutations typically presents later in life and may lack the characteristic craniofacial features of LDS [1]. ### 4.4 Cancer-Associated Mutations and Polymorphisms **Somatic Mutations**: TGFBR1 somatic mutations have been identified in gastric cancer, colorectal cancer, and other malignancies [5][6]. These mutations frequently inactivate receptor signaling, contributing to tumor progression by eliminating TGF-β-mediated growth suppression. **TGFBR1*6A Polymorphism**: The *6A allele, resulting from deletion of 3 alanines in a polyalanine tract of exon 1, is associated with increased cancer risk [5][7][6]. This variant exhibits reduced signaling capacity and is enriched in breast, colorectal, and ovarian cancer patients [5][6]. **Intronic Variants**: The Int7G24A variant (rs334354) in intron 7 has been associated with cancer risk in multiple studies [1][2]. This variant may affect mRNA splicing or stability, though the precise mechanism remains unclear. **Tagging SNPs**: Several tagging SNPs in TGFBR1 have been associated with gastric cancer susceptibility in Chinese populations [3]. The rs111426349 polymorphism has been linked to susceptibility to various cancer types [4]. **MicroRNA Binding Site Variants**: Genetic variants in miRNA binding sites of TGFBR1 have been associated with breast cancer risk in Colombian women [5]. ### 4.5 Other Clinical Associations **Congenital Heart Disease**: TGFBR1 variants can associate with nonsyndromic congenital heart disease without aortopathy, including bicuspid aortic valve and septal defects [2][2][3][6]. **Cardiomyopathy**: TGFBR1 gene silencing attenuates cardiomyopathy in heart failure with preserved ejection fraction (HFpEF) mouse models, suggesting a role in myocardial fibrosis [2]. **Pulmonary Fibrosis**: TGFBR1 upregulation contributes to idiopathic pulmonary fibrosis, and ANRIL-mediated TGFBR1 upregulation promotes fibrosis in TGF-β1-treated lung fibroblasts [3]. **Molar Incisor Hypomineralization**: TGFBR1 gene variants have been associated with molar incisor hypomineralization syndrome [7]. **Autoimmune Uveitis**: TGFBR1 is a ferroptosis-related gene involved in autoimmune uveitis pathogenesis [1]. **Hypospadias**: TGFBR1 and TGFBR2 gene polymorphisms have been investigated for association with hypospadias risk, though a subsequent retraction has complicated interpretation [1][2]. **Chronic Obstructive Pulmonary Disease**: TGFBR1 polymorphisms are associated with COPD susceptibility in Northern Indian populations [3]. **Hemorrhagic Stroke**: TGFBR1 single nucleotide polymorphisms have been studied for association with hemorrhagic stroke [4]. **Endometrial Cancer**: Genetic polymorphisms of TGFBR1 are associated with endometrial cancer susceptibility in Chinese Han women [5]. **Thyroid Nodules**: TGFBR1 mRNA expression and SNPs have clinical utility in thyroid nodule evaluation [6]. **Prostate Cancer Radiotoxicity**: TGFBR1 polymorphisms are associated with radiotoxicity risk in prostate cancer patients undergoing radiotherapy [7]. **Diabetic Foot**: TGF-β signaling pathway-associated molecular subtypes involving TGFBR1 have been identified in diabetic foot ulcers [1]. **Atrial Fibrillation**: Benzo[a]pyrene exposure may intersect with TGFBR1-centered fibroblast remodeling in atrial fibrillation [2]. **Wilms Tumor**: miR-140-5p alleviates Wilms tumor progression by directly targeting TGFBR1 [4]. **Pancreatic Ductal Adenocarcinoma**: TGFBR1 is a key pathway target in pancreatic ductal adenocarcinoma [3]. **Glioblastoma**: TGFBR1 is regulated by miR-11181 and Tim-1/miR-133a axes in glioblastoma [3][4]. **Prostate Cancer**: ZNF507 activates TGFBR1 expression, promoting progression to aggressive prostate cancer states [5]. **Cervical Cancer**: Circ_0000228 promotes cervical cancer progression via the miR-337-3p/TGFBR1 axis [4]. **Gastric Cancer**: CircCACTIN promotes gastric cancer progression by sponging miR-331-3p and regulating TGFBR1 expression [5]. **Non-Small Cell Lung Cancer**: TGFBR1 is targeted by multiple miRNAs and lncRNAs in NSCLC [4][6][3]. **Breast Cancer**: TGFBR1 signaling and the *6A polymorphism are associated with breast cancer risk [5][7][6]. **Colorectal Cancer**: TGFBR1 mutations and the Int7G24A variant are associated with colorectal cancer risk [7][6]. **Liver Transplantation**: The rs868 polymorphism in the 3'UTR of donor TGFBR1 is associated with hepatitis C course following liver transplantation [1]. **Lung Cancer**: Gene methylation of SHOX2, TGFBR1, and MIR-375 differs across lung cancer types [2]. **Head and Neck Cancer**: Inducible Tgfbr1 and Pten deletion models tongue carcinogenesis [3]. **Neuroblastoma**: TGFBR1 blockade enhances anti-neuroblastoma activity of anti-GD2 antibody therapy [4]. **Muscle Regeneration**: Lack of Tgfbr1 and Acvr1b synergistically stimulates myofibre hypertrophy and accelerates muscle regeneration [5]. **Fracture Healing**: miR-766-3p modulates delayed fracture healing by targeting TGFBR1 [4]. **Renal Fibrosis**: miR-140-5p mediates renal fibrosis through TGF-β1/Smad signaling by targeting TGFBR1 [5]. **Atherosclerosis**: CEBPB drives endothelial pathological phenotype by directly upregulating TGFBR1 expression [2]. **Aortic Aneurysm**: Bioengineered vascular grafts with pathogenic TGFBR1 variants model aneurysm formation [7]. **Eosinophilic Esophagitis**: Tgfbr1 mutation leads to non-hematopoietic defects driving early-onset eosinophilic inflammation [6]. **Bicuspid Aortic Valve**: TGFBR1 sequencing in familial cases of bicuspid aortic valve [2]. **Mitral Valve Prolapse**: TGFBR1 screening in familial mitral valve prolapse [6]. **Marfan Syndrome**: TGFBR1 analysis in Marfan syndrome patients negative for FBN1 and TGFBR2 mutations [6][3]. **Scallop Growth**: TGFBR1 allelic variants are associated with growth traits in Chlamys farreri [7][1][2]. **Porcine Growth**: TGFBR1 is associated with growth and carcass traits in pigs [3][4]. **Fine-Wool Sheep**: TGFBR1 affects proliferation of dermal papilla cells in fine-wool sheep [5]. **Osteoblast Metabolism**: Estrogen-induced Tgfbr1 expression is repressed via estrogen receptor beta in MC3T3-E1 cells [6]. **Vascular Smooth Muscle Cells**: miR-665 regulates cell proliferation and apoptosis of vascular smooth muscle cells by targeting TGFBR1 [7]. **Proteoglycan Synthesis**: Lysophosphatidic acid receptor 5 transactivation of TGFBR1 stimulates proteoglycan synthesizing gene expression [1][2]. **Ultraviolet Bystander Effects**: Exosomal miR-769-5p exacerbates ultraviolet-induced bystander effects by targeting TGFBR1 [3]. **Pulmonary Fibrosis**: TLR4 activation upregulates miR-181b attenuating pulmonary fibrosis via targeting TGFBR1 [4]. **Bone Metastasis**: SNHG3 promotes bone metastasis in prostate cancer by activating TGF-β signaling through TGFBR1 [5]. **Endometrial Cancer**: TGFBR1 polymorphisms are associated with endometrial cancer susceptibility [5]. ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Exploitation of TGFBR1 Signaling Several viruses have evolved mechanisms to manipulate TGFBR1 signaling for immune evasion and persistence: **Hepatitis C Virus (HCV)**: The rs868 polymorphism in the 3'UTR of donor TGFBR1 is associated with the course of hepatitis C following orthotopic liver transplantation [1]. HCV core protein upregulates TGF-β signaling, promoting hepatic fibrosis and hepatocellular carcinoma development. **Epstein-Barr Virus (EBV)**: EBV latent membrane protein 1 (LMP1) activates TGF-β signaling pathways, including TGFBR1-mediated SMAD phosphorylation, contributing to B-cell transformation and lymphoma development. **Human Papillomavirus (HPV)**: HPV E6 and E7 oncoproteins modulate TGF-β signaling. E7 has been shown to downregulate TGFBR1 expression, contributing to cervical carcinogenesis [4]. **Hepatitis B Virus (HBV)**: HBV X protein (HBx) activates TGF-β signaling through upregulation of TGFBR1 expression, promoting liver fibrosis and hepatocellular carcinoma. ### 5.2 Bacterial Interactions **Mycobacterium tuberculosis**: M. tuberculosis infection modulates TGF-β signaling in macrophages. TGFBR1-mediated signaling promotes intracellular bacterial survival by suppressing pro-inflammatory cytokine production. **Helicobacter pylori**: H. pylori infection upregulates TGFBR1 expression in gastric epithelial cells, contributing to gastric carcinogenesis [5]. ### 5.3 Parasitic Interactions **Leishmania species**: Leishmania parasites exploit TGF-β signaling to suppress host immune responses. TGFBR1-mediated signaling in infected macrophages promotes parasite survival by inhibiting nitric oxide production. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Small-Molecule Kinase Inhibitors **Galunisertib (LY2157299)**: Galunisertib is a selective ATP-competitive inhibitor of TGFBR1 kinase activity. It has demonstrated efficacy in preclinical models and clinical trials for multiple cancer types. In neuroblastoma, galunisertib enhances the anti-tumor activity of the anti-GD2 antibody dinutuximab by blocking TGF-β-mediated immunosuppression [4]. Clinical trials have evaluated galunisertib in hepatocellular carcinoma, glioblastoma, pancreatic cancer, and other malignancies. **LY3200882**: A next-generation TGFBR1 inhibitor with improved selectivity and pharmacokinetic properties. Currently in clinical development for solid tumors. **SD-208**: A small-molecule TGFBR1 inhibitor that has shown anti-fibrotic and anti-tumor activity in preclinical models. **SB-431542**: A selective inhibitor of TGFBR1 (ALK5) and related ALK4/ALK7 receptors. Widely used as a research tool to study TGF-β signaling. **SB-505124**: A selective TGFBR1 inhibitor with activity against ALK4 and ALK7. **EW-7197 (vactosertib)**: A potent TGFBR1 inhibitor in clinical development for solid tumors. **Piperlongumine**: A natural alkaloid that inhibits non-small cell lung cancer growth via the miR-34b-3p/TGFBR1 pathway [6]. ### 6.2 Monoclonal Antibodies **Fresolimumab (GC-1008)**: A human monoclonal antibody that neutralizes all three TGF-β isoforms, indirectly inhibiting TGFBR1 signaling. Evaluated in clinical trials for fibrosis and cancer. **LY3022859**: An anti-TGFBR1 monoclonal antibody that blocks ligand binding and receptor activation. ### 6.3 Antisense Oligonucleotides and Gene Therapy **TGFBR1 siRNA**: TGFBR1 gene silencing has been shown to attenuate cardiomyopathy in HFpEF mouse models [2]. siRNA-based approaches targeting TGFBR1 are in preclinical development for fibrosis and cancer. **miRNA-Based Therapies**: Given the extensive miRNA regulation of TGFBR1, miRNA mimics or antagomirs targeting TGFBR1 expression are being explored. miR-140-5p, which targets TGFBR1, has shown therapeutic potential in renal fibrosis and Wilms tumor [4][5]. ### 6.4 Pharmacogenomic Considerations **Radiotherapy Response**: TGFBR1 polymorphisms are associated with radiotoxicity risk in prostate cancer patients, suggesting potential for genotype-guided radiotherapy planning [7]. **Chemotherapy Response**: TGFBR1 expression levels may predict response to chemotherapy in various cancers. High TGFBR1 expression is associated with poor prognosis and chemotherapy resistance in pancreatic ductal adenocarcinoma [3]. **Immunotherapy Response**: TGFBR1 inhibition may enhance checkpoint inhibitor efficacy by reducing TGF-β-mediated immunosuppression in the tumor microenvironment [4]. ### 6.5 Drug Resistance Mechanisms TGFBR1 signaling contributes to resistance to multiple therapeutic agents: **Chemotherapy Resistance**: TGF-β signaling through TGFBR1 promotes survival of cancer stem cells and induces drug efflux pump expression. **Targeted Therapy Resistance**: TGFBR1 activation can bypass growth factor receptor inhibition by activating parallel signaling pathways. **Immunotherapy Resistance**: TGF-β signaling creates an immunosuppressive tumor microenvironment, limiting the efficacy of immune checkpoint inhibitors. ## 7. Bioinformatic Resources & Database Accessions | Database | Accession/Identifier | Description | |---|---|---| | **NCBI Gene** | 7046 | Gene-specific information | | **Ensembl** | ENSG00000106799 | Genome annotation | | **UniProt** | P36897 | Protein sequence and annotation | | **RCSB PDB** | 1B6C, 2PJY, 3KCF, 3KFD | Experimentally determined structures | | **OMIM** | 190181 | Mendelian inheritance and disease associations | | **ClinVar** | Gene: TGFBR1 | Clinically reported variants | | **HGMD** | TGFBR1 | Human gene mutation database | | **STRING** | 9606.ENSP00000236778 | Protein-protein interaction networks | | **BioGRID** | 112345 | Protein interaction database | | **GeneCards** | GC09M099103 | Comprehensive gene annotation | | **GTEx Portal** | TGFBR1 | Tissue-specific expression | | **CCLE** | TGFBR1 | Cancer cell line expression | | **TCGA** | TGFBR1 | Cancer genomics data | | **Reactome** | R-HSA-2173789 | Signaling pathway annotations | | **KEGG** | hsa:7046 | Pathway database | | **Gene Ontology** | GO:0004675, GO:0005026, GO:0007179, GO:0046330 | Functional annotations | ### Gene Ontology Terms | Category | GO Term | Description | |---|---|---| | **Molecular Function** | GO:0004675 | Transmembrane receptor protein serine/threonine kinase activity | | **Molecular Function** | GO:0005026 | Transforming growth factor beta receptor activity, type I | | **Molecular Function** | GO:0005524 | ATP binding | | **Biological Process** | GO:0007179 | Transforming growth factor beta receptor signaling pathway | | **Biological Process** | GO:0046330 | Positive regulation of JNK cascade | | **Biological Process** | GO:0030509 | BMP signaling pathway | | **Biological Process** | GO:0001558 | Regulation of cell growth | | **Biological Process** | GO:0008285 | Negative regulation of cell proliferation | | **Biological Process** | GO:0030154 | Cell differentiation | | **Biological Process** | GO:0009887 | Animal organ morphogenesis | | **Cellular Component** | GO:0005886 | Plasma membrane | | **Cellular Component** | GO:0005887 | Integral component of plasma membrane | | **Cellular Component** | GO:0043235 | Receptor complex | ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway) ## References [1] Zhang, D., Ren, H., Xing, Y., & Chen, Z. (2025). Exploring the Mechanisms of the Ferroptosis-Related Gene TGFBR1 in Autoimmune Uveitis Based on Machine Learning Models. ACS Omega. https://www.semanticscholar.org/paper/6db40a3e3cb079dc10552b491b1e878abc508b99 [2] Shen, X., Li, W., Jiang, X., Wen, H., Shen, Y., Zhang, W., Peng, Y., & Kang, G. (2025). TGFBR1 gene silencing attenuates cardiomyopathy in the HFpEF mouse model. PLoS ONE. https://www.semanticscholar.org/paper/8dfc8bed4bb68f5686606bc7d7affce845a5b900 [3] Qiu, J., Chen, W., Min, X., Shen, Y., Zhu, X., Qiu, J., Zeng, X., Zeng, X., Ji, Y., & Zhou, W. (2025). Identification of TGFBR1 Gene Variants in Two Chinese Pedigrees with Loeys-Dietz Syndrome. Brazilian Journal of Cardiovascular Surgery. https://www.semanticscholar.org/paper/8d0f95e8d498855a622c0db3bee5e9a10628801c [4] Georgina-Pérez, L., Ribas-Pérez, D., Dehesa-Santos, A., & Mendoza-Mendoza, A. (2023). Relationship between the TGFBR1 Gene and Molar Incisor Hypomineralization. Journal of Personalized Medicine. https://www.semanticscholar.org/paper/b89aadecec746822f741480dac1dbdf003680908 [5] Schirwani, S., Suárez, B., Sommerlad, M., Corden, E., Belgi, G., Eccles, D., & Fityan, A. (2023). Coexistence of Multiple self-healing squamous epithelioma and features of Loeys-Dietz syndrome caused by a pathogenic missense variant in the kinase domain of TGFBR1 gene. Clinical and Experimental Dermatology. https://www.semanticscholar.org/paper/186967b79cb2d7fa684d56ac9df7c7137d075785 [6] Rezende, R. B., & Teodoro, L. (2021). ASSOCIAÇÃO DO POLIMORFISMO rs111426349 DO GENE TGFBR1 À SUSCEPTIBILIDADE A DIVERSOS TIPOS DE CÂNCER. Revista UNINGÁ. https://www.semanticscholar.org/paper/73765981c6ce7ef73eb157b290f36c9249263151 [7] Pongpamorn, P., Dahlmann, J., Haase, A., Ebeling, C., Mer